DOCSLIB.ORG

Emerging Drugs of Abuse Modes of Administration

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

10/22/2018 Emerging Drugs of Abuse: The New Kids on the Block Jared O’Connor MS, MPH Raman Nagra Health Education and Outreach Specialist EWU Intern Washington Poison Center Eastern Washington University [email protected] [email protected] Emerging Drugs of Abuse • Overview • Nicotine • Cannabinoids • Opiates • Other Drugs of Abuse Always here to help, 24/7/365. Modes of Administration • 1. Inhalation (7‐10 sec) • 2. Injection • ▪ IV “slamming” (15‐30 sec) • ▪ SC “skin popping” (3‐5 min) • ▪ IM “muscling” (5‐7 min) • 3. Mucosal Absorption (?) • ▪ snorting • ▪ buccal • ▪ vaginal/rectal “bumping” • 4. Oral (20‐30 min) • 5. Contact Absorption (?) • ▪intraocular • ▪ lingual • ▪ transdermal Always here to help, 24/7/365. 1 10/22/2018 Synthetics • Drugs like Molly, MDMA, 2CE, bath salts, synthetic marijuana small segment of drug use • Synthetic opiates are an increasing problem • Present a problem because they rapidly change and can be deadly • Synthetics tend to have more profound effects then their natural counterparts • Greater receptor affinity • More addictive Always here to help, 24/7/365. Origin • Per DEA, many synthetic drugs coming from China • Bath salts • Spice/K2 • Methamphetamine in the state produced locally • Krokodil coming from Russia or produced locally • Lack of quality control and standardization Always here to help, 24/7/365. Nicotine Always here to help, 24/7/365. 2 10/22/2018 What is in the e‐juice/e‐liquid? • Liquids or “Juices” typically have 4 ingredients: • Liquid nicotine • Propylene glycol • Vegetable glycerin • “Flavoring” • LD 50 in mice is 1mg per lb • Can have 36mg ML • 15ml a bottle Always here to help, 24/7/365. What is in the e‐juice/e‐liquid? • High doses of Nicotine • Nausea • Lethargy • Central nervous depression • Respiratory depression • Death Always here to help, 24/7/365. Always here to help, 24/7/365. 3 10/22/2018 Always here to help, 24/7/365. Cannabis Always here to help, 24/7/365. Cannabis • In general... • Toxicity is mild • Effects not prolonged and usually not life threatening • Potentially problematic in children who ingested edibles or abuse of hash oil • Psychiatric effects predominate • Usually a sense of well being and relaxation, euphoria, “dream‐like”state • Use of marijuana in naïve users or using large amounts can produce more significant symptoms • Anxiety, paranoia, acute psychosis or obsessional thinking • Impairment of speech and fine motor skills • Increased risk for MVA Always here to help, 24/7/365. 4 10/22/2018 Cannabis • Various different cannabinoids out there • THC most common and used to achieve the characteristic high • CBD popular in medical marijuana due to its anti‐inflammatory/analgesic effects • Smoking marijuana produces a high within 8‐10 minutes and last around 4‐6 hours • Impairment, including fine motor skill impairment, can last up to 24 hours • Ingesting marijuana produces high from 1 hour to 3 hours • Potential for “Overdose” if patient redoses multiple times Always here to help, 24/7/365. Cannabis and Health • Extremely addictive • 1/10 users of marijuana will become addicted • Under 18, 1/6 will become addicted • Health Effect • Problems with memory, attention, and learning • Anxiety, paranoia, and sometimes extreme psychotic reactions • Can impact the development of the brain until age 25 • Harmful to lung tissue • Many of the same carcinogens as in tobacco smoke • Small blood vessel damage • Second hand smoking Always here to help, 24/7/365. Cannabis “Waxes” • Butane Hash Oil (BHO) is a wax‐like or pollen‐like residue • Placed directly onto coil that is then turned on • Need temperatures to reach 350‐450 ˚F to release cannabinoids Homemade BHO Wikimedia commons G Pen Coil http://www.npr.org/sections/health-shots/2014/04/18/302992602/pot-smoke-and-mirrors-vaporizer- pens-hide-marijuana-use Always here to help,Micro G Pen & Container 24/7/365. 5 10/22/2018 Cannabis • Butane Hash Oil (BHO) or dab • Dangerous manufacturing which can be explosive • Highly concentrated form of THC • Up to 95% THC • Plant typically up to 20% (8‐12% more common) Always here to help, 24/7/365. Vaping & Dabbing: Not quite the same http://googleweed.com/ Always here to help, 24/7/365. Cannabis edibles • Homemade edibles • Unknown concentration or if other drugs present • Many edibles easily confused with commercial products intended for children • Recent Crackdown might outlaw commercial Edibles Always here to help, 24/7/365. 6 10/22/2018 WAPC Trends ‐ Marijuana Always here to help, 24/7/365. Common Symptoms For Cannabis Exposure Top 5 symptoms for marijuana exposure include: 1. Drowsiness/Lethargy 2. Increased heartrate 3. Agitated/Irritable 4. Vomiting 5. Nausea Always here to help, 24/7/365. Synthetic Cannabinoids • Illegal as of May 2013 • DEA classified as Class 1 Drug • Several drugs • Spice/K2 • Up to 800x more powerful then marijuana • B‐FUBINACA/ AK‐47 24 Karat Gold • 50 x more powerful then K2 • Per DEA, Synthetics are coming from China, same with synthetic opiates • Patents are published and use by foreign nations Always here to help, 24/7/365. 7 10/22/2018 Synthetic Cannabinoids • Extremely addictive • Compared to Heroin or Cocaine • Health effects • Severe agitation and anxiety. • Fast, racing heartbeat and higher blood pressure. • Nausea and vomiting. • Muscle spasms, seizures, and tremors. • Intense hallucinations and psychotic episodes. • Suicidal and other harmful thoughts and/or actions. • Can cause Death • Hyperthermia, Seizures, Heart attack, Coma, Kidney damage, & Brain Edema among others • Jan 1,2016 to Jun 30th, Poison Centers received 4,270 calls regarding exposures • Few cases in Washington Always here to help, 24/7/365. Opioids Always here to help, 24/7/365. What is An Opiate/Opioid? • Opiate is a drug derived from Opium • Morphine • Codeine • Heroin • Opioids refer to synthetic or semi‐synthetic drugs that attach to the Opioid receptors to produce morphine like effects • Semi‐synthetic Opioids are derived from an opiate: oxycodone, hydrocodone, hydromorphone • Synthetic Opioids are completely lab made: methadone, fentanyl, tramadol, naloxone • Synthetics tend to have more profound effects than their natural counterparts • Greater receptor affinity • More addictive 24 "Opiate Abuse." DrugAbuse.com. N.p., 13 Aug. 2016. Web. 26 Jan. 2017. Available Alwaysat: http://drugabuse.com/library/opiate-abuse/#signs-and-symptoms here to help, 24/7/365. 8 10/22/2018 Opioids Swallowed Snorted Smoked Injected Injection especially risky • Spread of HIV/AIDS and Hepatitis C • Damage veins and cause abscesses • Can lead to bacterial infection of the blood and heart problems Always here to25 help, 24/7/365. Opioids • Depending on type, there are different side effects • Analgesia (inability to feel pain) • Euphoria • Respiratory depression • Body less sensitive to hypercapnia (Feed back that causes you to breath) • Can be fatal • Cardiac arrhythmias • Methadone and propoxyphene • Seizures– • tramadol, meperidine, and propoxyphene • Muscle rigidity following rapid IV injection of fentanyl (chest wall rigidity) • Effects and be magnified with use of benzodiazepines (e.g.Xanax) or alcohol Always here to help, 24/7/365. OpioidsDid you know… • Drug overdoses are the leading cause of accidental death • Drug overdoses have surpassed car crashes and firearm related deaths. • 2 Washingtonians die from the opioid cause every day Always here to help, 24/7/365. 9 10/22/2018 Opioids Always here to help, 24/7/365. WAPC – in 2016 by age Always here to help, 24/7/365. Naloxone (Narcan) Used to reverse an opiate overdoes • Is an opiate that has competitive affinity for the same receptors • Limitations • Utility decrease with Synthetic's, due to their greater affinity • Halflife is often shorter then competing opiate • Various ways to administer • Spray • Injection • IV drip Always here to help, 24/7/365. 10 10/22/2018 Naloxone (Narcan®) Half life in hours 9 • Limitations 8 • Efficacy may decrease with synthetics, due to their 7 greater affinity for the receptor • Synthetics such as Fentanyl and Carfentanil 6 • Half‐life is often shorter then competing opiate 5 4 7.7 7 • Various ways to administer 3 • Spray 2 4 • Injection (IM or IV) 1 1 0 0.5 Heroin Naloxone Hydrocodone Fentanyl Carfentanil Always here to help, 24/7/365. Fentanyl 100x more potent than morphine Used medically as a painkiller • Lollipop • Patch • Used patches present risks Often adulterated into heroin or counterfeit oral painkillers Overdose and death likely underreported • Clinical presentation similar to other opioid overdoses • May not show up on urine drug screen Standard therapy and doses of naloxone may not be of benefit due to drugs affinity to receptors • Airway support • IV naloxone Always here to help, 24/7/365. Carfentanil Analog of synthetic opioid fentanyl • 10,000x more potent than morphine • 100x more potent than fentanyl Often adulterated into heroin or counterfeit oral painkillers 2mg of carfentanil, enough to Standard therapy and doses of naloxone unlikely to incapacitate a 2,000lb elephant, next to a be of benefit penny. Source: DEA Always here to help, 24/7/365. 11 10/22/2018 W‐Series Compounds Class of opioids identified at Univ. of Alberta in 1982 • W-18, 100x more potent than fentanyl, • sold as street drugs in North America • Not regulated • Recent death in Calgary Narcan is ineffective Always here to help, 24/7/365. Krokodil Contains desomorphine • Derivative of morphine Highly adulterated and dirty drug • Codeine from cough syrup • Gasoline fuel • Lighter fluid • Red phosphorus •
Recommended publications
  • Interview with Pierre Pichot

    Interview with Pierre Pichot

    PSYCHOPHARMACOLOGY AND THE HISTORY OF PSYCHIATRY PIERRE PICHOT Could we begin with your recollections of the 1955 Paris meeting, which was effectively the first world wide meeting on chlorpromazine. The meeting was organised in Paris by Jean Delay. It was supported by Specia, the pharmaceutical firm which had produced chlorpromazine, which was a branch of the Rhone Poulenc Group. For the first time people engaged in what was called psychopharmacology came together. They came from many countries, including the United States. The efficacy of the drug and the mechanism of action were discussed. However, at that time the biochemistry of the brain, as it exists now, was unknown. It was only at the beginning of the 60s, that we began to speak of the role of the neurotransmitters in the action of both neuroleptic drugs and antidepressants and of their potential abnormalities in the disease process. So in practice 1955 was only a meeting on therapy with chlorpromazine. I have always been very much impressed by the fact that chlorpromazine, which had been introduced only 3 years before, was already used all over the world. Theoretical ideas take usually a very long time to travel from one country to another, and sometimes they never make it. I quote always, the case of Karl Jaspers’ General Psychopathology, which is considered in the German speaking world as one of the basic books of psychiatry. This was published in 1913 but appeared in English translation only in 1963, 50 years later and, even then, a paper published in the American Journal of Psychiatry wrote ingenuously that, until this publication, many psychiatrists in the United States had not realised that Jaspers was not only a philosopher, but also a psychiatrist.
  • Assessing Neurotoxicity of Drugs of Abuse

    Assessing Neurotoxicity of Drugs of Abuse

    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Assessing Neurotoxicity of Drugs of Abuse 136 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Assessing Neurotoxicity of Drugs of Abuse Editor: Lynda Erinoff, Ph.D. NIDA Research Monograph 136 1993 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGMENT This monograph is based on the papers and discussions from a technical review on “Assessing Neurotoxicity of Drugs of Abuse” held on May 20-21, 1991, in Bethesda, MD. The technical review was sponsored by the National Institute on Drug Abuse (NIDA). COPYRIGHT STATUS NIDA has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
  • Characterization of Multiple Sites of Action of Ibogaine

    Characterization of Multiple Sites of Action of Ibogaine

    ——Chapter 6—— CHARACTERIZATION OF MULTIPLE SITES OF ACTION OF IBOGAINE Henry Sershen, Audrey Hashim, And Abel Lajtha Nathan Kline Institute Orangeburg, New York 10962 I. Introduction.................................................................................................................. II. Issues Related to Ibogaine in the Treatment of Drug Dependence............................. A. Dopamine as a Primary Site of Drug-Mediated Responses .................................. B. Ibogaine or Its Metabolite and Acute versus Long-Term Effect........................... C. Single or Multiple Sites of Action of Ibogaine ..................................................... III. Effect of Ibogaine on Drug-Induced Behavior............................................................ IV. Binding Site Activity ................................................................................................... A. Relevant Site of Action.......................................................................................... V. Functional Activity ...................................................................................................... VI. Stimulant Drug Actions/Behaviors.............................................................................. VII. Current Non-Ibogaine Drug Treatment Protocols ....................................................... VIII. Conclusions.................................................................................................................. References...................................................................................................................
  • The Challenge of Managing Wounds in the Injecting Drug- Dependent Patient

    The Challenge of Managing Wounds in the Injecting Drug- Dependent Patient

    Clinical PRACTICEClinical DEVELOPMENT REVIEW The challenge of managing wounds in the injecting drug- dependent patient Managing wounds in the patient who injects drugs is complex for healthcare professionals. As with the non- drug taking population, the problems of mobility, odour from the wound, social limitation and pain still occur, but fears of discrimination may lead to reluctance to seek medical intervention, potentially leading to slower recovery and chronicity. This article focuses on the problems encountered by injecting drug users, a group that can suffer significant wound care issues, including infection, wound abscess and fistula formation, along with other management problems, such as a reciprocal mistrust of healthcare professionals. Andy Roden Irrespective of the route of doses of opioid are given to patients KEY WORDS administration, once heroin is taken with chronic pain.’ Heroin users report a feeling of well-being, Drug addiction relaxation and safety, which Finnie and It is quite possible that a patient Nicolson (2002; p. s18) describe as ‘like may have a tolerance/addiction to Analgesics being wrapped up in a warm blanket’. opioids, which requires analgesia, as Wound care management It is these properties, along with the well as pain from a chronic wound, Healthcare professionals euphoria associated with taking heroin, which also needs managing. This can which makes it such a potentially be a difficult task for the healthcare powerfully addictive drug. professional and is one where specialist help from a drug and alcohol specialist eroin (diacetylmorphine or team will be required. By administering diamorphine) is a powerful There is no therapeutic opioids, practitioners may also be seen Hanalgesic synthesised from discovery that has been so as condoning or reinforcing the drug- the group of mixed alkaloids present great a blessing and so great taking behaviour.
  • Additional Requested Drugs

    Additional Requested Drugs

    PART 1 PART PATIENT PRESCRIBED MEDICATIONS: o ACTIQ o DESIPRAMINE o HYDROCODONE o MORPHINE o ROXICODONE o ADDERALL o DIAZEPAM* o HYDROMORPHONE o MS CONTIN o SOMA o ALPRAZOLAM* o DILAUDID o IMIPRAMINE o NEURONTIN o SUBOXONE o AMBIEN o DURAGESIC o KADIAN o NORCO o TEMAZEPAM o AMITRIPTYLINE o ELAVIL o KETAMINE o NORTRIPTYLINE o TRAMADOL* o ATIVAN o EMBEDA o KLONOPIN o NUCYNTA o TYLENOL #3 o AVINZA o ENDOCET o LORAZEPAM o OPANA o ULTRAM o BUPRENEX o FENTANYL* o LORTAB o OXYCODONE o VALIUM o BUPRENORPHINE o FIORICET o LORCET o OXYCONTIN o VICODIN o BUTRANS o GABAPENTIN o LYRICA o PERCOCET o XANAX o CLONAZEPAM* o GRALISE o METHADONE o RESTORIL TO RE-ORDER CALL RITE-PRINT 718/384-4288 RITE-PRINT CALL TO RE-ORDER ALLIANCE DRUG PANEL (SEE BELOW) o ALCOHOL o BARBITURATES o ILLICITS o MUSCLE RELAXANTS o OPIODS (SYN) ETHANOL PHENOBARBITAL 6-MAM (HEROIN)* CARISPRODOL FENTANYL* BUTABARBITAL a-PVP MEPROBAMATE MEPERIDINE o AMPHETAMINES SECOBARBITAL BENZOYLECGONINE NALOXONE AMPHETAMINE PENTOBARBITAL LSD o OPIODS (NATURAL) METHADONE* METHAMPHETAMINE BUTALBITAL MDA CODEINE METHYLPHENEDATE MDEA MORPHINE o NON-OPIOID o BENZODIAZEPINES MDMA ANALGESICS o OPIODS (SEMI-SYN) o ANTICONVULSIVES ALPRAZOLAM* MDPV TRAMADOL BUPRENORPHINE* GABAPENTIN CLONAZEPAM* MEPHEDRONE TAPENTADOL DIHROCODEINE PREGABALIN DIAZEPAM METHCATHINONE DESOMORPHINE o NON-BENZODIAZEPINE FLUNITRAZEPAM* METHYLONE HYDROCODONE HYPNOTIC o ANTIDEPRESSANTS FLURAZEPAM* PCP HYDROMORPHONE ZOLPIDEM* AMITRIPTYLINE LORAZEPAM THC* OXYCODONE DOXEPIN OXAZEPAM CBD ° OXYMORPHONE o MISCELLANEOUS DRUGS IMIPRIMINE
  • Predictors of Skin and Soft Tissue Infections Among Sample of Rural Residents Who Inject Drugs

    Predictors of Skin and Soft Tissue Infections Among Sample of Rural Residents Who Inject Drugs

    Baltes et al. Harm Reduct J (2020) 17:96 https://doi.org/10.1186/s12954-020-00447-3 RESEARCH Open Access Predictors of skin and soft tissue infections among sample of rural residents who inject drugs Amelia Baltes1* , Wajiha Akhtar2, Jen Birstler3, Heidi Olson‑Streed4, Kellene Eagen1, David Seal5, Ryan Westergaard2 and Randall Brown1 Abstract Introduction: Skin and soft tissue infections (SSTIs) are among the leading causes of morbidity and mortality for people who inject drugs (PWID). Studies demonstrate that certain injection practices correlate with SSTI incidence among PWID. The opioid epidemic in the USA has particularly afected rural communities, where access to preven‑ tion and treatment presents unique challenges. This study aims to estimate unsafe injection practices among rural‑ dwelling PWID; assess treatments utilized for injection related SSTIs; and gather data to help reduce the overall risk of injection‑related SSTIs. Methods: Thirteen questions specifc to SSTIs and injection practices were added to a larger study assessing unmet health care needs among PWID and were administered at six syringe exchange programs in rural Wisconsin between May and July 2019. SSTI history prevalence was estimated based on infections reported within one‑year prior of response and was compared to self‑reported demographics and injection practices. Results: Eighty responses were collected and analyzed. Respondents were white (77.5%), males (60%), between the ages 30 and 39 (42.5%), and have a high school diploma or GED (38.75%). The majority of respondents (77.5%) reported no history of SSTI within the year prior to survey response. Females were over three times more likely to report SSTI history (OR 3.07, p 0.038) compared to males.
  • Msm, Crystal Meth and Intravenous Drug Use in a Sexual Setting

    Msm, Crystal Meth and Intravenous Drug Use in a Sexual Setting

    TINA AND SLAMMING MSM, CRYSTAL METH AND INTRAVENOUS DRUG USE IN A SEXUAL SETTING Leon Knoops, Ingrid Bakker, Renate van Bodegom, Paul Zantkuijl 1 COLOPHON GLOSSARY Authors Ass play: anal insertion of fingers, fist, dildos or other Leon Knoops, Ingrid Bakker, Renate van Bodegom - objects Mainline en Paul Zantkuijl - Soa Aids Nederland Barebacking: anal sex without a condom BDSM: Bondage and Discipline, Dominance and Interviews with MSM Submission, Sadism and Masochism Leon Knoops - Mainline • role play involving physical restraints, and focusing on intense stimulation and/or playing with power relations Interviews with professionals • kinky sex Ingrid Bakker - Mainline en Willem van Aaken - Booty-bumping: a mode of administering a water-soluble Soa Aids Nederland drug by injecting it into the rectum with a needleless syringe Editing Bo!om: passive sexual role Ejay de Wit - Loaded Content Chems: drugs, chemical substances Chemsex: having sex while under the influence of drugs/ Reference editing chemical substances Mary Hommes - Soa Aids Nederland Coming out: self-disclosure of sexual orientation to the outside world English translation: Coming down: immediate a"ermath of drug use, during The English Writer which the physical and psychological consequences of use are experienced Proofreading Crystal meth: methamphetamine (see: Tina) Joost Breeksema Downer: narcotic drug (inhibitory effect on central nervous system) Design and layout Entactogen: a class of psychoactive drugs that produce planpuur. experiences of emotional communion, oneness,
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept

    Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept

    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
  • Emerging Drug Trends 2014

    Emerging Drug Trends 2014

    EMERGING DRUG TRENDS – 2014 Special Research Report • Regional Organized Crime Information Center Emerging Drug Trends Table of Contents Opioid Abuse .................................................... 2 By ROCIC Publications Specialist Jennifer Adkins Opiate Abuse .................................................... 7 © Regional Organized Crime Information Center Synthetic Cathinones ..................................... 13 ew drugs are emerging at an unprecedented rate as manufacturers Synthetic Cannabinoids ................................. 18 of “legal high” products use new chemicals to replace those that Phenethlyamines ............................................ 22 N Party Pills ...................................................27 are banned. These new chemicals take the place of heroin, morphine, and amphetamines. These drugs are highly accessible, touted as legal, Herbal Drugs ..............................................29 Sources of Information ...............................32 and perceived as safe. This Special Research Report was supported by Grant No. 2011-RS-CX-K007, awarded by the Bureau of Justice Assistance, Office of Justice Programs, U.S. However, despite the popularity in designer drugs and legal high Department of Justice. The Office of Justice Programs also coordinates the activi- ties of the Bureau of Justice Statistics, the National Institute of Justice, the Office of products, the abuse of heroin and prescription painkiller medication Juvenile Justice and Delinquency, and the Office for Victims of Crime.
  • Influence of Antipsychotic and Anticholinergic Loads on Cognitive Functions in Patients with Schizophrenia

    Influence of Antipsychotic and Anticholinergic Loads on Cognitive Functions in Patients with Schizophrenia

    Hindawi Publishing Corporation Schizophrenia Research and Treatment Volume 2016, Article ID 8213165, 10 pages http://dx.doi.org/10.1155/2016/8213165 Research Article Influence of Antipsychotic and Anticholinergic Loads on Cognitive Functions in Patients with Schizophrenia Michael Rehse,1,2 Marina Bartolovic,1 Katlehn Baum,3 Dagmar Richter,1 Matthias Weisbrod,1,3 and Daniela Roesch-Ely1 1 Department of Psychiatry, University of Heidelberg, 69115 Heidelberg, Germany 2Psychiatrisches Zentrum Nordbaden, 69168 Wiesloch, Germany 3Department of Psychiatry and Psychotherapy, SRH Hospital Karlsbad-Langensteinbach, 76307 Karlsbad, Germany Correspondence should be addressed to Daniela Roesch-Ely; daniela [email protected] Received 14 October 2015; Revised 19 February 2016; Accepted 7 March 2016 AcademicEditor:L.Citrome Copyright © 2016 Michael Rehse et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Many patients with schizophrenia show cognitive impairment. There is evidence that, beyond a certain dose of antipsychotic medication, the antipsychotic daily dose (ADD) may impair cognitive performance. Parallel to their D2 receptor antagonism, many antipsychotics show a significant binding affinity to cholinergic muscarinic receptors. Pharmacological treatment with a high anticholinergic daily dose (CDD) significantly impairs attention and memory performance. To examine the relationships between individual cognitive performance and ADD and/or CDD, we conducted a retrospective record-based analysis of a sample of = 104 in patients with a diagnosis of schizophrenia, all of whom had completed a comprehensive neuropsychological test battery. To calculate the individual ADD and CDD, the medication at the time of testing was converted according to equivalence models.
  • Skin Popping Scars – a Telltale Sign of Past and Present Subcutaneous Drug Abuse

    Skin Popping Scars – a Telltale Sign of Past and Present Subcutaneous Drug Abuse

    DOI 10.1515/crpm-2012-0056 Case Rep. Perinat. Med. 2012; 1(1-2): 37–39 Amos Grunebaum* and Daniel Skupski Skin popping scars – a telltale sign of past and present subcutaneous drug abuse Abstract Case Background: Identifying women with past and present drug abuse is an essential aspect of prenatal care. A 33-year-old primiparous pregnant woman was admit- Case: Despite having typical telltale physical signs of ted to the hospital at 38 weeks with a history of premature prior subcutaneous drug injections, a 33-year-old preg- rupture of membranes (PROM) about 5 h before admis- nant woman who had regular prenatal care visits with sion. She received prenatal care from a private obstetrician multiple obstetric care providers was only identified as a from the 6th week of pregnancy. At 34 weeks, she moved drug abuser after a cesarean section, when her skin scars to a different city where she continued prenatal care with were identified by one provider as the result of “skin another private obstetrician. popping” related to injections of illicit drugs before this She did not mention her history of drug use during her pregnancy. prenatal care, and physical examinations done by both Conclusion: This case demonstrates that obstetricians obstetricians were unremarkable. On admission, her cervix must become aware of the telltale signs of drug abuse, was 1 cm dilated, not effaced, with the vertex at −3 station. such as subcutaneous injections (skin popping) with The estimated fetal weight was 3600 g, and the fetal heart illicit drugs leading to scaring of the arms and other parts rate was reassuring.
  • Alcohol and Drug Education/Sun Protection

    Alcohol and Drug Education/Sun Protection

    HEALTH INITIATIVE LUNCH AND LEARN III: ALCOHOL AND DRUG EDUCATION/SUN PROTECTION K A T I E L. HOWE: HEALTH EDUCATOR MARK FINK: ASSISTANT DIRECTOR, FITNESS T H U R S D A Y , M A R C H 6 , 2014 CAMPUS LIFE CENTER QUIET ROOM 1 2 : 0 0 - 12:30 P.M. OVERVIEW • Alcohol Education: • Drinking Responsibly • Binge Drinking • Alcohol Poisoning • Drug Education: • Recreational Drugs • Prescription Drugs • Sun Protection: • Vitamin D • Skin Cancer • Sun Screens ALCOHOL EDUCATION • Not all drinks are equal!! • The alcohol content differs among each type of drink. Beer for example can range from 4% to upwards of 20% (high gravity). • Blood Alcohol Content (BAC): The percentage of alcohol in the blood. The greater percentage of alcohol a drink contains, the faster a person’s BAC will rise. DRINKING RESPONSIBLY • Abstain from drinking until you are of legal age. • Always practice moderation. • 2 drinks for men, 1 drink for women. • Always appoint a designated driver. • Never pressure anyone to drink. • Be a role model. • Nutrition • 7 calories/gram of Alcohol • Most alcoholic beverages are approximately 125-150 calories, however once you begin mixing with soda, juice, etc. the calories begin to pile on. If you choose to drink liquor try mixing with water or club soda. Also add extra ice cubes or keep it on the rock. This dilutes the cocktail allowing you to sip on the drink longer, decreasing the number of drinks consumed and also increases water intake. BINGE DRINKING/ALCOHOL POISONING Binge Drinking (Episodic Excessive Drinking) Alcohol Poisoning • Men: 5 or more drinks.